Although the effect of the complement C5a receptor inhibitor avacopan on ILD has not been studied, given that C5aR blockade may influence fibrotic and tissue-repair pathways in the kidney, it is plausible that avacopan could also mitigate pulmonary fibrosis (19). This evidence concerns the gene C5AR1 and interstitial lung disease.